Physicochemical Properties
| Molecular Formula | C44H54CL2N8O5 |
| Exact Mass | 844.3594222 |
| CAS # | 2227029-18-5 |
| Related CAS # | 2227029-18-5 |
| Appearance | Typically exists as solid at room temperature |
| InChi Key | LLBSNYUMQZVIBK-UKMLIFFGSA-N |
| InChi Code | InChI=1S/C44H54Cl2N8O5/c1-5-27(4)41(44(59)50-30-16-18-35-36(23-30)52-38(51-35)21-28-24-48-34-13-10-9-12-31(28)34)54-39(55)14-8-6-7-11-19-47-43(58)37(20-26(2)3)53-40(56)25-49-42(57)32-22-29(45)15-17-33(32)46/h9-10,12-13,15-18,22-24,26-27,37,41,48H,5-8,11,14,19-21,25H2,1-4H3,(H,47,58)(H,49,57)(H,50,59)(H,51,52)(H,53,56)(H,54,55)/t27-,37+,41+/m1/s1 |
| Chemical Name | 2,5-dichloro-N-[2-[[(2S)-1-[[7-[[(2S,3R)-1-[[2-(1H-indol-3-ylmethyl)-3H-benzimidazol-5-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-7-oxoheptyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]benzamide |
| Synonyms | TUS-007 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | KRas G12D; KRas G12V |
| ln Vitro | TUS-007 is toxic to cells expressing KRAS G12D/V and has a strong inhibitory effect on them [1]. Rather of impacting KRAS G12C, TUS-007 (100 μM; 72 h) indirectly affects the viability of low-RAS electrodes expressing KRAS G12D/V [1]. The fraction of annexin V-positive SW1990 cells in the bladder is increased by TUS-007 (20-160 μM; 72 h) [1]. |
| ln Vivo | TUS-007 (80 mg/kg i.p. or 160 mg/kg lateral; every 3 days for 21 days) suppresses KRAS G12V-driven tumors in vivo in the SW620-Luc xenograft model [ TUS -007 shows anti-tumor effect even in orthotopic xenograft models [1]. |
| Cell Assay |
Apoptosis Analysis[1] Cell Types: SW1990 Cell Tested Concentrations: 20 μM, 40 μM, 80 μM and 60 μM Incubation Duration: 72 hrs (hours) Experimental Results: Annexin V positive compared to cells treated with DMSO or RAS-SOS-NH2 The proportion of apoptotic SW1990 cells increased. |
| Animal Protocol |
Animal/Disease Models: immunodeficient mice carrying SW620-Luc cells [1] Doses: 80mg/kg or 160mg/kg Route of Administration: intraperitoneal (ip) injection or po (oral gavage); once every 3 days for 21 days Experimental Results: Dramatically attenuated tumor progression without affecting weight. |
| References | [1]. Imanishi S, et al. In vivo KRAS G12D/V degradation mediated by CANDDY using a modified proteasome inhibitor. bioRxiv, 2021: 2021.04. 23.441075. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |